Lawrence, KS, United States of America

Marc Iacobucci

USPTO Granted Patents = 3 

 

Average Co-Inventor Count = 7.0

ph-index = 1


Company Filing History:


Years Active: 2022-2024

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: The Innovations of Marc Iacobucci

Introduction

Marc Iacobucci is an accomplished inventor based in Lawrence, KS (US). He has made significant contributions to the field of medical technology, particularly in the treatment of epithelial cysts. With a total of 3 patents to his name, Iacobucci's work has the potential to impact patient care positively.

Latest Patents

One of Marc Iacobucci's latest patents focuses on the treatment of epithelial cysts through intracystic injection of antineoplastic particles. This innovative method involves using compositions that include taxane particles, such as paclitaxel and docetaxel, to treat conditions like pancreatic cysts. This approach represents a significant advancement in the management of such medical conditions.

Career Highlights

Iacobucci's career is marked by his dedication to developing effective treatment methods. His work at Crititech, Inc. has allowed him to explore and implement groundbreaking techniques in the medical field. His innovative spirit and commitment to improving patient outcomes are evident in his patent portfolio.

Collaborations

Marc Iacobucci has collaborated with notable professionals in his field, including Gere S diZerega and Michael Baltezor. These partnerships have contributed to the development and refinement of his innovative ideas.

Conclusion

Marc Iacobucci's contributions to medical technology through his patents and collaborations highlight his role as a significant inventor in the field. His work continues to pave the way for advancements in the treatment of epithelial cysts, showcasing the importance of innovation in healthcare.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…